Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
CAR-T: what is next?
YJ Chen, B Abila, Y Mostafa Kamel - Cancers, 2023 - mdpi.com
Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with
early-phase clinical studies showing encouraging responses. However, the transcriptional …
early-phase clinical studies showing encouraging responses. However, the transcriptional …
Recent advances in hyperthermia therapy‐based synergistic immunotherapy
The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
E Liu, D Marin, P Banerjee… - … England Journal of …, 2020 - Mass Medical Soc
Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
[HTML][HTML] Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome
Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …
[HTML][HTML] ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
DW Lee, BD Santomasso, FL Locke, A Ghobadi… - Biology of blood and …, 2019 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most
promising therapies for hematologic malignancies. Two CAR T products were recently …
promising therapies for hematologic malignancies. Two CAR T products were recently …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
[HTML][HTML] Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Highlights•CAR T cells are associated with unique side-effects.•Cytokine release syndrome
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …